Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very ...
The incidence of cutaneous T-cell lymphoma increased in US patients aged 0-29 years from 1997 to 2019, with larger rises in younger children, males, and Hispanics.
While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...
The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...
Low-grade lymphomas are a non-Hodgkin lymphoma (NHL) subtype. They typically grow more slowly and cause fewer symptoms than NHLs. They still require ongoing monitoring and treatment. There are two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results